Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) - Kris,M.; Herbst,R. (Lung Cancer, 2000)